Not provided
Not provided
Not provided
Not provided
Not provided
Business reasons
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is an open-label Phase 2 study evaluating the long term safety and tolerability of GFB-887 in patients with focal segmental glomerulosclerosis (FSGS), and treatment-resistant minimal change disease (TR-MCD)
Participants will be enrolled from the ongoing GFB-887 multiple ascending dose trial. Participants will be transitioned to a 200 mg QD dose level regardless of the dose received in the previous study although the data review team (DRT) and Medical Monitor may elect to decrease or increase the dose to minimize adverse events or improve clinical efficacy. The DRT may also elect to change dosing levels due to emerging data on GFB-887. Participants will take GFB-887 once daily at home. A phone visit will be conducted at Week 4 and at Week 8 to assess safety and tolerability. Participants will return to the clinic for follow up visits at Weeks 12, 24, 36, 48, and every 24 weeks thereafter through approximately 3 years from the time of the participant's first dose to evaluate long-term safety and durability of response (for up to approximately 13 scheduled in-clinic visits).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 200 mg Dose Cohort | Experimental | Participants who received GFB-887 or placebo in GFB-887-201 will receive GFB-887 at a daily dose level of 200 mg regardless of original dose level. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| GFB-887 | Drug | GFB-887 is a potent, small molecule inhibitor of TRPC5. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence and severity of adverse events | Incidence and severity of adverse events | Approximately 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Percent reduction in urine protein:creatinine ratio (UPCR) from baseline | Percent reduction in urine protein:creatinine ratio (UPCR) from baseline | Approximately 3 years |
| Proportion of participants achieving modified partial remission status |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Academic Medical Research Institute (AMRI) | Los Angeles | California | 90022 | United States | ||
| Amicis Research Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Open label study extension
Not provided
Not provided
Not provided
Not provided
Proportion of participants achieving modified partial remission status
| Approximately 3 years |
| Proportion of participants achieving complete remission status | Proportion of participants achieving complete remission status | Approximately 3 years |
| Proportion of participants with a UPCR decrease of at least 30% from baseline | Proportion of participants with a UPCR decrease of at least 30% from baseline | Approximately 3 years |
| Proportion of participants with a UPCR decrease of at least 40% from baseline | Proportion of participants with a UPCR decrease of at least 40% from baseline | Approximately 3 years |
| Proportion of participants with a UPCR decrease of at least 50% from baseline | Proportion of participants with a UPCR decrease of at least 50% from baseline | Approximately 3 years |
| Time to maximal percent reduction in UPCR from baseline | Time to maximal percent reduction in UPCR from baseline | Approximately 3 years |
| Summary of plasma pharmacokinetic (PK) concentrations: Dose proportionality | Dose proportionality of GFB-887 | Approximately 3 years |
| Summary of Plasma PK concentrations (AUCinf) | Area under the plasma concentration-time curve from time zero to infinity | Approximately 3 years |
| Summary of Plasma PK concentrations (AUClast) | Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration | Approximately 3 years |
| Summary of Plasma PK concentrations (Cmax) | Maximum observed plasma concentration | Approximately 3 years |
| Changes in estimated glomerular filtration rate (eGFR) including slope | Glomerular filtration rate will be estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on serum creatinine | Approximately 3 years |
| Northridge |
| California |
| 91324 |
| United States |
| Kidney and Hypertension Center - Apple Valley | Victorville | California | 92395 | United States |
| University of Colorado Anschutz Medical Center | Aurora | Colorado | 80045 | United States |
| Colorado Kidney Care (Denver Nephrology) | Denver | Colorado | 80230 | United States |
| Boise Kidney and Hypertension Institute | Nampa | Idaho | 83687 | United States |
| NANI Research, LLC | Hinsdale | Illinois | 60521 | United States |
| St. Clair Nephrology | Roseville | Michigan | 48066 | United States |
| Clinical Research Consultants | Kansas City | Missouri | 64111 | United States |
| Icahn School of Medicine at Mount Sinai | New York | New York | 10029 | United States |
| The Ohio State University Wexner Medical Center | Columbus | Ohio | 43210 | United States |
| Southeast Renal Research Institute | Chattanooga | Tennessee | 37404-2743 | United States |
| Prolato Clinical Research Center | Houston | Texas | 77054 | United States |
| Clinical Advancement Center, PLLC | San Antonio | Texas | 78212 | United States |
| Tranquility Research | Webster | Texas | 77598 | United States |
| Utah Kidney Center | Salt Lake City | Utah | 84115 | United States |
| Providence Medical Research Center | Spokane | Washington | 99204 | United States |
| ID | Term |
|---|---|
| D007674 | Kidney Diseases |
| D005921 | Glomerulonephritis |
| D009393 | Nephritis |
| D009401 | Nephrosis |
| ID | Term |
|---|---|
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided